<DOC>
	<DOCNO>NCT00003117</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness paclitaxel without carboplatin treat patient recurrent , stage IIIB , stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Paclitaxel With Without Carboplatin Treating Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival patient non-small cell lung cancer treat paclitaxel alone combination carboplatin . II . Compare quality life patient treat chemotherapy regimen . III . Compare response rate toxic effect two regimen patient population . OUTLINE : This randomize study . Patients stratify accord stage disease ( stage IIIB v stage IV v recurrent progressive surgery and/or radiotherapy ) , performance status ( 0-1 v 2 ) , age ( 70 vs 70 ) . Patients randomize one two treatment arm . Arm I receive paclitaxel IV 3 hour day 1 course . Arm II receive paclitaxel Arm I , follow carboplatin IV 1 hour . Treatment repeat every 21 day 6 course absence tumor progression unacceptable toxicity . Quality life assessment conduct treatment 2 , 6 , 9 , 12 month . Patients follow every 3 month 2 year , every 6 month disease progression death .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven nonsmall cell lung cancer ( adenocarcinoma , large cell , squamous cell , mixture ) Stage IIIB due following : Malignant pleural effusion Supraclavicular node involvement Contralateral hilar node involvement Not eligible CALGB protocol combine therapy chest irradiation Stage IV Any stage recur progressed surgery radiotherapy Measurable evaluable disease Does include follow : Bone metastases Pleural peritoneal effusion Irradiated lesion , unless progression document radiation therapy No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL SGOT le 2 time upper limit normal ( ULN ) Renal : Creatinine great 2 time ULN Other : No prior concurrent malignancy except : Curatively treat carcinoma situ cervix Curatively treat breast cancer Curatively treat basal cell squamous cell skin cancer At least 5 year since nonrecurrent primary tumor surgically resect without administration adjuvant radiation therapy chemotherapy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy No concurrent chemotherapy Endocrine therapy : No concurrent hormones except steroid adrenal failure , hormone nondisease related condition ( e.g. , insulin diabetes ) , dexamethasone Radiotherapy : At least 2 week since prior radiotherapy See Disease Characteristics Surgery : Prior surgery allow See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>